Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01778803|
Recruitment Status : Completed
First Posted : January 29, 2013
Last Update Posted : May 17, 2017
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Ovarian Cancer||Drug: defactinib Drug: Paclitaxel||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/Ib Study of Paclitaxel in Combination With VS-6063, a Focal Adhesion Kinase Inhibitor, in Subjects With Advanced Ovarian Cancer|
|Actual Study Start Date :||February 26, 2013|
|Actual Primary Completion Date :||February 23, 2015|
|Actual Study Completion Date :||February 23, 2015|
Experimental: defactinib (VS-6063) plus paclitaxel
Oral defactinib (VS-6063) administered twice daily, in combination with intravenous paclitaxel administered on Days 1, 8, and 15 of a 28 day cycle.
Other Name: VS-6063
Other Name: Taxol
- Number of patients experiencing treatment-related adverse events as assessed by CTCAE v4.03 (Common Toxicity Criteria for Adverse Effects)during the study (safety and tolerability). [ Time Frame: From start of treatment to end of treatment, an expected average of 12 weeks ]Adverse events and their frequency, duration and severity, as determined based on CTCAE 4.03
- Determine the recommended phase 2 dose (RP2D) based on a combination of maximum tolerated dosed (MTD), review of adverse event data and review of AUC, Tmax and t1/2 obtained from PK data during the dose escalation phase of the study. [ Time Frame: From start of treatment to end of cycle 1 (4 week cycles) ]The RP2D will be determined based on the maximum tolerated dose (MTD) of defactinib (VS-6063) in combination with paclitaxel as determined by number of participants with dose limiting toxicities (DLTs) related to defactinib in combination with paclitaxel
- Proportion of patients treated with paclitaxel and defactinib (VS-6063) with progression-free survival using Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 [ Time Frame: Every 2 cycles up to end of treatment, an expected average of 12 weeks ]Response rate and progression-free survival, as determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1
- Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, AUC (Area Under Curve) 0-t. [ Time Frame: Time points at Day 1 and Day 15 in Cycle 1 ]Plasma concentration of defactinib (VS-6063)
- Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, maximum concentrations (Cmax) [ Time Frame: Time points at Day 1 and Day 15 in Cycle 1 ]Plasma concentration of defactinib (VS-6063)
- Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, Time to maximum concentrations (Tmax) [ Time Frame: Time points at Day 1 and Day 15 in Cycle 1 ]Plasma concentration of defactinib (VS-6063)
- Pharmacokinetics (PK) estimates of defactinib (VS-6063) when co-administered with paclitaxel, , estimates of concentration 1/2 life (T1/2) [ Time Frame: Time points at Day 1 and Day 15 in Cycle 1 ]Plasma concentration of defactinib (VS-6063)
- Evaluate biomarkers of defactinib (VS-6063) activity [ Time Frame: Day 1 and Day 10 of treatment ]Pre and post dose biomarkers (including but not limited to FAK and phospho-FAK, as well as specific markers for cell cycle inhibition, apoptosis and cancer stem cells) in archival tumor tissue and new biopsy samples
- Examine if the tumor expression status correlates with response to defactinib (VS-6063) therapy [ Time Frame: From start of treatment to end of treatment, an expected average of 12 weeks ]Tumor expression status (pFAK and other biomarkers) compared with response to defactinib, as determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Female|
|Accepts Healthy Volunteers:||No|
- Able to provide signed and dated informed consent prior to initiation of any study procedures.
- Female subjects aged ≥ 18 years.
- Advanced or refractory ovarian cancer, confirmed histologically.
- Subjects may have received up to 4 prior lines of chemotherapy for their metastatic disease.
- All persistent clinically significant toxicities from prior chemotherapy must be ≤ Grade 1.
- ECOG performance status of 0 or 1 (refer to Appendix A), measured within 72 hours before the start of treatment.
- Predicted life expectancy of ≥ 3 months.
- Adequate renal function [creatinine ≤ 1.5x ULN (upper limit of normal)] or GFR of ≥ 50mL/min.
- Adequate hepatic function (total bilirubin ≤ 1.5x ULN for the institution; AST [aspartate transaminase] and ALT [alanine transaminase] ≤ 3x ULN, or ≤ 5x ULN if due to liver involvement by tumor).
- Adequate bone marrow function (hemoglobin ≥ 9.0 g/dL; platelets≥ 100 x109cells/L; absolute neutrophil count ≥ 1.5x109 cells/L).
- Corrected QT interval (QTc) < 470 ms (as calculated by the Fridericia correction formula).
- Negative pregnancy test for females of child-bearing potential; must be surgically sterile, postmenopausal, or willing and able to be compliant with a contraceptive regimen (double barrier birth control) during and for 3 months after the treatment period.
- Willing and able to participate in the trial and comply with all trial requirements.
- Gastrointestinal (GI) condition which could interfere with the swallowing or absorption of study medication.
- Uncontrolled or severe concurrent medical condition (including uncontrolled brain metastases). Stable brain metastases either treated or being treated with a stable dose of steroids/anticonvulsants, with no dose change within 28 days prior to the first dose of study drug, will be allowed.
- History of upper gastrointestinal bleeding, ulceration, or perforation within 12 months prior to the first dose of study drug.
- Known history of Gilbert's Syndrome.
- Known history of stroke or cerebrovascular accident within 6 months prior to the first dose of study drug.
- Subjects with known infection with human immunodeficiency virus (HIV) or Acquired Immune Deficiency Syndrome (AIDS) (testing not required).
- Subjects with Hepatitis A, B or C (testing not required).
- Subjects being actively treated for a secondary malignancy.
- Cancer-directed therapy (chemotherapy, radiotherapy, hormonal therapy, biologic or immunotherapy, etc.) within 28 days of the first dose of study drug or 5 half-lives, whichever is shorter.
- Major surgery within 28 days prior to the first dose of study drug.
- Use of an investigational drug within 28 days or 5 half-lives (whichever is shorter) prior to the first dose of study drug. A minimum of 10 days between termination of the investigational drug and administration of the study treatment is required. In addition, any drug-related toxicity except alopecia should have recovered to grade 1 or less.
- Pregnant or breastfeeding.
- Any evidence of serious active infections.
- Uncontrolled or severe cardiovascular disease, including myocardial infarct or unstable angina within 6 months prior to study treatment, New York Heart Association (NYHA) Class II or greater congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.
- Uncontrolled intercurrent illness including symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01778803
|United States, Florida|
|Florida Cancer Specialists|
|Sarasota, Florida, United States|
|United States, Oklahoma|
|University of Oklahoma|
|Oklahoma City, Oklahoma, United States|
|United States, Tennessee|
|Sarah Cannon Research Institute|
|Nashville, Tennessee, United States, 37203|
|Study Chair:||Hagop Youssoufian, MD||Verastem, Inc.|
|Responsible Party:||Verastem, Inc.|
|Other Study ID Numbers:||
|First Posted:||January 29, 2013 Key Record Dates|
|Last Update Posted:||May 17, 2017|
|Last Verified:||January 2017|
Carcinoma, Ovarian Epithelial
Endocrine Gland Neoplasms
Neoplasms by Site
Genital Neoplasms, Female
Endocrine System Diseases
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents, Phytogenic
Molecular Mechanisms of Pharmacological Action